|29th September 2020||David J. Marguglio||20,000||Open or private sale||$0.80||$16,000.00|
|29th September 2020||Robert O Hopkins||20,000||Open or private sale||$0.80||$16,000.00|
|18th August 2020||Karen K. Daniels||5,480||Open or private sale||$0.87||$4,790.07|
|18th August 2020||Ronald B. Moss||8,749||Open or private sale||$0.87||$7,647.50|
|18th August 2020||Dennis J Phd Carlo||10,929||Open or private sale||$0.87||$9,553.04|
|18th August 2020||David J. Marguglio||8,749||Open or private sale||$0.87||$7,647.50|
|18th August 2020||Robert O Hopkins||7,418||Open or private sale||$0.87||$6,484.07|
|19th May 2020||Karen K. Daniels||4,855||Open or private sale||$0.56||$2,719.29|
|18th May 2020||Robert O Hopkins||6,532||Open or private sale||$0.56||$3,658.57|
|18th May 2020||David J. Marguglio||7,734||Open or private sale||$0.56||$4,331.81|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of -2/10.
Adamis Pharmaceuticals Corp. engages in the discovery, development and sales of pharmaceutical, specialty biopharmaceutical and other drug products. The company offers Symjepi product for allergy, respiratory, opioid overdose, and erectile dysfunction (ED) markets.